US Stock MarketDetailed Quotes
ARQT Arcutis Biotherapeutics
- 8.490
- -0.010-0.12%
Close Aug 16 16:00 ET
- 8.520
- +0.030+0.35%
Post 20:01 ET
992.40MMarket Cap-4994P/E (TTM)
8.585High8.170Low2.75MVolume8.530Open8.500Pre Close23.12MTurnover3.20%Turnover RatioLossP/E (Static)116.89MShares13.17052wk High5.32P/B729.34MFloat Cap1.76052wk Low--Dividend TTM85.91MShs Float40.880Historical High--Div YieldTTM4.88%Amplitude1.760Historical Low8.403Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Arcutis Biotherapeutics Stock Forum
Arcutis Biotherapeutics reported strong Q2 2024 financial results, with net product revenues of $30.9M for the ZORYVE franchise, representing a 547% increase year-over-year and 43% growth quarter-over-quarter. The company saw improved gross-to-net (GTN) margins, now in the high 50% range. Arcutis entered a co-promotion agreement with Kowa Pharmaceuticals to expand ZORYVE's reach in primary care and pediatric offices. They also submitted an sNDA for ZORYV...
Larger Image: tradingview.com...
$Arcutis Biotherapeutics (ARQT.US)$
No comment yet